Literature DB >> 18411175

Vasoactive intestinal polypeptide: biologic role in health and disease.

S I Said1.   

Abstract

Vasoactive intestinal polypeptide (VIP), a neuropeptide with wide distribution in the central and peripheral nervous systems, has a broad spectrum of biologic actions. Usually acting as a neurotransmitter or neuromodulator but sometimes also as a blood-borne hormone, it participates in the regulation of a variety of major body functions and may be an important factor in the pathogenesis of several diseases.

Year:  1991        PMID： 18411175     DOI： 10.1016/s1043-2760(05)80006-2

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN： 1043-2760            Impact factor:   12.015


  7 in total

Review 1.  Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.

Authors:  Anthony J Harmar; Jan Fahrenkrug; Illana Gozes; Marc Laburthe; Victor May; Joseph R Pisegna; David Vaudry; Hubert Vaudry; James A Waschek; Sami I Said
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 2.  VIP as a cell-growth and differentiation neuromodulator role in neurodevelopment.

Authors:  J M Muller; V Lelievre; L Becq-Giraudon; A C Meunier
Journal:  Mol Neurobiol       Date:  1995 Apr-Jun       Impact factor: 5.590

3.  Vasoactive intestinal peptide impairs leucocyte migration but fails to modify experimental murine colitis.

Authors:  R Newman; N Cuan; T Hampartzoumian; S J Connor; A R Lloyd; M C Grimm
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

4.  VIP and PACAP are autocrine factors that protect the androgen-independent prostate cancer cell line PC-3 from apoptosis induced by serum withdrawal.

Authors:  Irene Gutiérrez-Cañas; Nieves Rodríguez-Henche; Oscar Bolaños; María J Carmena; Juan C Prieto; María G Juarranz
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

5.  Therapeutic efficacy of stable analogues of vasoactive intestinal peptide against pathogens.

Authors:  Jenny Campos-Salinas; Antonio Cavazzuti; Francisco O'Valle; Irene Forte-Lago; Marta Caro; Stephen M Beverley; Mario Delgado; Elena Gonzalez-Rey
Journal:  J Biol Chem       Date:  2014-04-04       Impact factor: 5.157

Review 6.  International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide.

Authors:  A J Harmar; A Arimura; I Gozes; L Journot; M Laburthe; J R Pisegna; S R Rawlings; P Robberecht; S I Said; S P Sreedharan; S A Wank; J A Waschek
Journal:  Pharmacol Rev       Date:  1998-06       Impact factor: 25.468

7.  Colonic levels of vasoactive intestinal peptide decrease during infection and exogenous VIP protects epithelial mitochondria against the negative effects of IFNγ and TNFα induced during Citrobacter rodentium infection.

Authors:  Arpan K Maiti; Sinan Sharba; Nazanin Navabi; Sara K Lindén
Journal:  PLoS One       Date:  2018-09-25       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.